Murchinson’s NRX Pharmaceuticals NRXP Stock Holding History

Murchinson’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,790	Closed	-$166K	–	155
2021 Q3	$166K	Buy	+1,790	New	+$233K	0.08%	72

Other funds holding NRXP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Murchinson's NRXP Position: Q4 2021 in Review

Murchinson sold out of NRX Pharmaceuticals (NRXP) in Q4 2021, closing a stake of 1,790 shares — an estimated $166K sold.

Murchinson first reported a position in NRXP in Q3 2021 and held it in 1 quarter. The position peaked at $166K in Q3 2021. 38 funds tracked by Wall St. Rank hold NRXP as of Q4 2021.

Murchinson reported no remaining NRX Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Murchinson sold 1,790 NRX Pharmaceuticals shares in Q4 2021, an estimated $166K.
Murchinson first reported a position in NRX Pharmaceuticals in Q3 2021 and held it in 1 quarter.
Murchinson's NRX Pharmaceuticals position peaked at $166K in Q3 2021.
38 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2021.

Based on Murchinson's 13F filing for Q4 2021, filed 14 Feb 2022.